Incidence, risk factors, and outcome of BK polyomavirus infection after kidney transplantation

Figure 1 Distribution of specific causes of kidney allograft loss in the study population. PVAN: Polyomavirus-associated nephropathy.

Figure 2 Crude cumulative incidence of BK-viremia in the study cohort considering death and graft failure as competing events. BKV: BK-viremia.

Figure 3 Kaplan-Meier patient survival curves. A: kidney transplant recipients with (dashed line) or without (continuous line) BK-viremia; B: kidney transplant recipients with (dashed line) or without (continuous line) polyomavirus-associated nephropathy. BKV: BK-viremia; PVAN: Polyomavirus-associated nephropathy.

Figure 4 Kaplan-Meier overall graft survival curves. A: kidney transplant recipients with (dashed line) or without (continuous line) BK-viremia; B: kidney transplant recipients with (dashed line) or without (continuous line) Polyomavirus-associated nephropathy. BKV: BK-viremia; PVAN: Polyomavirus-associated nephropathy.

Figure 5 Crude cumulative incidence of graft failure considering death as a competing risk. A: kidney transplant recipients with (dashed line) or without (continuous line) BK-viremia; B: kidney transplant recipients with (dashed line) or without (continuous line) Polyomavirus-associated nephropathy. BKV: BK-viremia; PVAN: Polyomavirus-associated nephropathy.

Figure 6 Crude cumulative incidence of graft failure considering death as a competing risk and excluding any events within thirty days of transplant. A: kidney transplant recipients with (dashed line) or without (continuous line) BK-viremia; B: kidney transplant recipients with (dashed line) or without (continuous line) Polyomavirus-associated nephropathy. BKV: BK-viremia; PVAN: Polyomavirus-associated nephropathy.